Prognostic score for synchronous metastatic rectal cancer: A real-world study

Archive ouverte

Muzellec, Léa | Campion, Loïc | Bachet, Jean-Baptiste | Taieb, Julien | Fremont, Elodie | Senellart, Hélène | Moreau, Johanna | Bouché, Olivier | Garric, Marie | Guimbaud, Rosine | Greilsamer, Charlotte | Bodère, Anaïs | Lièvre, Astrid | Girot, Paul | Edeline, Julien | Tougeron, David | Bennouna, Jaafar | Touchefeu, Yann

Edité par CCSD ; Elsevier -

International audience. Background: Prognostic factors of metastatic rectal cancer are not well known.Aim: The objective of this study was to identify prognostic factors of overall survival (OS) in a cohort of patients with non-resectable synchronous metastatic rectal cancer.Methods: Patients were retrospectively enrolled from 18 French centres. Univariate and multivariate analyses were performed to identify prognostic factors for OS. A simple score was derived from this a development cohort RESULTS: A total of 243 patients with metastatic rectal cancer were included in the study. Median OS was 24.4 months, 95% CI [19.4-27.2]. Among patients with non-resected metastases (n=141), six independent prognostic factors associated with better OS were identified in multivariate analysis: primary tumour surgery, WHO score 0-1, middle or upper rectal tumour, lung metastases only, systemic chemotherapy and targeted agent in first line. A prognostic score individualized three groups, each factor counting for one point in the score (<3, = 3 et > 3). Their median OS were respectively 27.9 months, 95% CI [21.7-35.1], 17.1 months [11.9-19.7] (HR2/1=2.08, 95%, CI [1.31-3.30], p2/1=0.002) and 9.1 months [4.9-11.7] (HR3/2=2.32, 95% CI [1.38-3.92], p3/2=0.001).Conclusion: A prognostic score for non-resectable synchronous metastatic rectal cancer can be proposed to classify patients in three prognostic groups.

Consulter en ligne

Suggestions

Du même auteur

Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors

Archive ouverte | Girot, Paul | CCSD

International audience. Introduction: Oxaliplatin-based regimens have shown promising antitumor activity in digestive neuroendocrine tumors (NETs); however, the available data are limited. Our aim was to assess the ...

Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors

Archive ouverte | Girot, Paul | CCSD

International audience. OBJECTIVE: Temozolomide (TMZ) is an alkylating agent frequently used in well-differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very variable responses. O-methylguanine-D...

Predictive Factors of Chemotherapy Initiation after Biliary Drainage for Advanced Biliary Tract Cancer: A Retrospective Multicenter Study

Archive ouverte | Azarfane, Miloud | CCSD

International audience. Background and Aims: In unresectable biliary tract cancers, the management of biliary obstruction is often the first step before introduction of chemotherapy. Our aim was to study the predict...

Chargement des enrichissements...